|
Profile Details
|
| Renier J. Brentjens |
|
Affiliations:
|
Memorial Sloan- Kettering Cancer Center
|
| |
|
|
| , US |
| Phone: |
| Fax: |
|
My Blogs:
|
| My Twitter Hashtags: |
|
| |
| Age:
|
| Bio: |
|
| |
| Specialty: |
| Oncology |
| |
| Presented at Events Covering: |
| , Biology, Biotechnology, Cancer Biology, Cell Biology, Epidemiology, Genomics, Hematology, Hepatology, Histology, Immunology, Leukemia, Microscopy, Molecular Biology, Oncology, Peptides, Pharmacology, Proteomics, Stem Cells, Translational Research |
| |
| Areas of Interest: |
|
| |
| Hobbies: |
|
| |
| General Comments: |
|
|
| BSN Rank:
114 / 548
(What's this?) |
|
Accomplish Score: 2317
|
|
Popularity Score: 6
|
|
# in My Circle: 0
|
|
# in My Org(s): 1
|
| We'll Post Your CV for Free! |
| |
| |
|
Speaking/Presenting-Abstract/Poster at Mtg: 110 (1430 / 3)
|
|
| |
|
Honors and Awards: 17 (170 / 0)
|
-
Inventor of the Year Award (2014)
-
NY Intellectual Property Law Association (2014)
-
Sir William Osler Young Investigator Award (2013)
|
| |
|
Clinical Trial Activity: 0 (0 / 0)
|
|
| |
|
Grant Support: 11 (99 / 0)
|
-
Adoptive Therapy with CD19 Targeted EBV-specific Donor T Cells in Pediatric Patients with Relapsed B cell ALL (2011 - Present)
-
A phase I clinical trial of consolidation therapy with autologous T cells genetically targeted to the CD19 antigen in high risk CLL patients following upfront chemotherapy with pentostatin, cyclophosphamide, and rituximab (2011 - Present)
-
Innovationsin the structures, functions and targets of monoclonal antibody-based drugs for
cancer (scFv secreting CAR T cells that modulate the tumor microenviroment and host
anti-tumor response) (2015)
|
| |
|
Patents Pending: 0 (0 / 0)
|
|
| |
|
Journal - Editor/Reviewer: 14 (98 / 0)
|
-
Lymphoma Research Foundation (2013)
-
Israel Science Foundation (2013)
-
Medical Research Council, United Kingdom (2013)
|
| |
|
Peer Reviewed Papers, Books, Chapters: 75 (450 / 0)
|
-
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. (2014)
-
IL-12 Secreting CD19-targeted Cord Blood-derived T Cells for the Immunotherapy of B Cell Acute Lymphoblastic Leukemia (2014)
-
Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. (2014)
|
| |
|
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
|
|
| |
|
Membership in Professional Societies: 23 (69 / 0)
|
-
American Society for Clinical Investigation (ASCI) (2015)
-
International Society for Cellular Therapy (ISCT) (2014)
-
Interurban Clinical Club (2014)
|
| |
|
White Papers: 0 (0 / 0)
|
|
| |
| Registered on BiotechScienceNews: 1 |
|
How We Rank
